Cartalax vs kpv
updated
Cartalax (tier C) vs kpv (tier B): what each is, why each got its grade, half-life and source counts side by side.
Cartalax · tier C
an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.
tier rationale
C-tier applies only to identity-verified synthetic L-Ala-L-Glu-L-Asp. The molecule is defined, has cell and animal observations, and has sparse human evidence in a poorly reported 29-person saline-controlled assignee-patent example. It cannot grade higher because the patent omits important design, group-level outcome, and safety detail; no independent peer-reviewed replication, formal pharmacokinetic study, independent toxicology package, or regulator-reviewed product was located. A product with unresolved sequence or extract composition does not inherit this grade.
kpv · tier B
tiny three-amino-acid peptide for inflammation. IBD, eczema, autoimmune. none of α-MSH's tanning or appetite side effects.
tier rationale
B-tier because the preclinical evidence is substantial and the mechanism is well-characterized, but human clinical trials are limited and U.S. compounding status is unsettled. KPV appears in combination blends like KLOW and has a coherent mucosal anti-inflammatory thesis, but it does not have phase 3 evidence or a formal approval pathway. Pharmacologically elegant, clinically underbuilt.
at a glance
| Cartalax | kpv | |
|---|---|---|
| tier | C | B |
| category | healing / tissue | healing / tissue |
| sources | 5 | 25 |
| claims evaluated | 5 | 6 |
| half-life | unknown; no measured concentration-time half-life | short in plasma; stable in GI tract |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.